H1 2026
Filed Sep 21, 2026Abivax reported a €165.9 million IFRS net loss for the first half of 2026, increased R&D and pre-commercial spending, and cash runway into Q4 2029 following its early July public offering.
The company extended its projected cash runway into Q4 2029 and advanced pre-commercial capabilities, but operating loss, financial loss, and operating cash use increased materially during H1 2026.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total operating incomeother | €2.5M | – | – |
| Research and development costsother | €107.9M | – | – |
| Research and development costs as a percentage of operating expensesother | 75.5% of operating expenses | – | – |
| Sales and marketing costsother | €4.6M | – | – |
| Sales and marketing costs as a percentage of operating expensesother | 3.2% of operating expenses | – | – |
| General and administrative costsother | €30.4M | – | – |
| General and administrative costs as a percentage of operating expensesother | 21.3% of operating expenses | – | – |
| Operating lossother | €140.3M | – | – |
| Financial lossother | €31.4M | – | – |
| Net loss before taxother | €171.7M | – | – |
| Income taxother | €5.8M | – | – |
| Net loss for the periodother | €165.9M | – | – |
| Cash flows used in operating activitiesother | €102.5M | – | – |
| Cash flows provided by investing activitiesother | €1.5M | – | – |
| Cash flows used in financing activitiesother | €39.3M | – | – |
| Effect of movements in exchange rates on cash heldother | €6.2M | – | – |
| Revaluation of cash equivalents measured at fair valueother | €5.4M | – | – |
| Decrease in cash and cash equivalentsother | €128.7M | – | – |
| Cash, cash equivalents and short-term investmentsother | €402.4M | – | – |
| Cash and cash equivalentsother | €388M | – | – |
| Short-term investments included in other current assetsother | €14.4M | – | – |
| Non-current assetsother | €34.6M | – | – |
| Other current assetsother | €39.6M | – | – |
| Total assetsother | €462.2M | – | – |
| Borrowings, notes and derivative instrumentsother | €1.2M | – | – |
| Royalty certificatesother | — | – | – |
| Other non-current liabilitiesother | €24.1M | – | – |
| Other current liabilitiesother | €70.6M | – | – |
| Total liabilitiesother | €95.9M | – | – |
| Total shareholders' equityother | €366.3M | – | – |
| Total liabilities and shareholders' equityother | €462.2M | – | – |
Into Q4 2029; end of 2026; mid-2027 outlook
- NoteProjected cash runway into Q4 2029 based on current operating assumptions.
- NoteEnd of 2026 – Planned NDA submission for obefazimod in UC.
- NoteMid-2027 – Topline results from the Phase 2b ENHANCE-CD induction trial evaluating obefazimod in CD.
- NoteOctober 2026 – Participation at United European Gastroenterology Week (UEGW).
Capital returns
- On May 7, 2026, the Company completed the repurchase and cancellation of all outstanding royalty certificates for total consideration of $90 million (approximately €76.5 million), comprising $45 million in cash and $45 million in equity through the issuance of 403,347 ordinary shares represented by ADSs.
- The royalty certificate transaction resulted in an expense of approximately €43.2 million in the second quarter of 2026 and the derecognition of a €5.8 million deferred tax liability, with a corresponding tax benefit recognized for the six months ended June 30, 2026.
- On July 6, 2026, Abivax completed an underwritten public offering of 7,360,000 American Depositary Shares. Aggregate gross proceeds were approximately $920 million, equivalent to approximately €807.4 million, before deduction of underwriting commissions and offering expenses. Net proceeds were approximately $874.1 million, equivalent to approximately €767.1 million.
What drove it
- R&D expense increased by €29.9 million, predominantly driven by a €6.8 million increase related to new indications, a €4.6 million increase in transversal activities, a €6.3 million increase related to the Crohn's disease clinical program, and a €8.5 million increase related to the ulcerative colitis clinical program.
- G&A expense increased by €14.1 million, primarily reflecting an €8.6 million increase in personnel costs and a €4.5 million increase in consulting and professional fees.
- Sales and marketing expense increased by €3.1 million due to continued preparation for potential future U.S. sales and commercialization efforts for obefazimod.
- The company appointed Chris Rabbat, Ph.D. as Chief Medical Officer successor and Tim Kelly as Chief Technical Officer, both effective immediately, to support potential commercialization readiness.
- The company reported positive ABTECT maintenance trial updates in June 2026 and a positive pre-NDA interaction with the FDA in July 2026.
Concerns
- Net loss for the period increased to €165.9 million from €100.8 million.
- Operating loss increased to €140.3 million from €93.7 million.
- Financial loss increased to €31.4 million from €7.1 million.
- Cash flows used in operating activities increased to €102.5 million from €66.6 million.
- Sales and marketing costs are expected to continue to accelerate in preparation for commercial launch.
- The company identified uncertainties related to research and development, future clinical data and analysis, regulatory decisions, and funding requirements.
What to watch
- October 2026 participation at United European Gastroenterology Week.
- End of 2026 planned NDA submission for obefazimod in UC.
- Mid-2027 topline results from the Phase 2b ENHANCE-CD induction trial evaluating obefazimod in CD.
- Execution of commercial CMC, Quality, IT, medical, and supply-readiness activities ahead of potential commercialization.
- Cash runway into Q4 2029 based on current operating assumptions.
Balance sheet and cash flow
- Cash, cash equivalents and short-term investments were €402.4 million as of June 30, 2026, including cash and cash equivalents of €388.0 million and certain short-term investments of €14.4M.
- Cash and cash equivalents were €516.7 million as of December 31, 2025.
- Cash flows used in operating activities were €102.5 million for the six months ended June 30, 2026, compared with €66.6 million for the six months ended June 30, 2025.
- Cash flows used in financing activities were €39.3 million for the six months ended June 30, 2026, compared with €16.6 million for the six months ended June 30, 2025.
- Borrowings, notes and derivative instruments were €1.2 million as of June 30, 2026, compared with €1.9 million as of December 31, 2025.
- Total liabilities were €95.9 million and total shareholders' equity was €366.3 million as of June 30, 2026.
Analysis
Abivax remained a clinical-stage company during H1 2026, with total operating income of €2.5 million and no reported revenue line or commercial segments. The period was characterized by expanding investment in obefazimod development and launch preparation. R&D costs reached €107.9 million, while sales and marketing costs reached €4.6 million as the company prepared for potential U.S. commercialization.
The cost base increased across development and infrastructure. R&D costs increased by €29.9 million, driven by new indications, CMC and supply-chain work, the Crohn's disease program, and ulcerative colitis program activity. G&A costs increased by €14.1 million, reflecting personnel costs, share-based compensation-related costs, and consulting and professional fees for future operating infrastructure. These cost increases contributed to operating loss of €140.3 million and net loss of €165.9 million.
Cash use also increased. Cash flows used in operating activities were €102.5 million for the first half, and the company reported a €128.7 million decrease in cash and cash equivalents. At June 30, cash, cash equivalents and short-term investments were €402.4 million. The balance sheet also reflected the elimination of royalty certificates following the May 7 repurchase and cancellation transaction.
Liquidity was materially strengthened after period end through the July underwritten public offering, which generated approximately €767.1 million in net proceeds. Abivax stated that the June 30 cash position together with those proceeds provides projected runway into Q4 2029. The next key operating milestones are the planned NDA submission for obefazimod in UC at the end of 2026 and topline Phase 2b ENHANCE-CD induction data in mid-2027.
Management is also building commercial-stage capabilities before any potential launch. Chris Rabbat is set to succeed Fabio Cataldi as Chief Medical Officer in the fourth quarter of 2026, while Tim Kelly has been appointed Chief Technical Officer. The leadership changes and higher CMC, Quality, IT, medical, and sales-and-marketing investment underscore the company's transition planning, while clinical, regulatory, and funding risks remain central to execution.
Management, verbatim
As we prepare Abivax for its next phase of growth and the potential commercialization of obefazimod, we are continuing to strengthen the leadership and capabilities needed to support that evolution.
Marc de Garidel, Chief Executive Officer of Abivax
Not in the filing
stated, not guessed- Revenue was not reported.
- Segment revenue and segment profit metrics were not reported.
- Gross profit and gross margin were not reported.
- A total operating expenses line was not reported.
- EPS was not reported.
- Non-GAAP or adjusted financial metrics were not reported.
- Free cash flow was not reported.
- Dividends and share repurchases were not reported.
- No prior outlook section was provided, so comparison with prior guidance is unavailable.
- Year-over-year and quarter-over-quarter percentage changes were not printed for the reported financial-statement line items.
- Prior-quarter financial-statement comparisons were not reported.
- A current-period total debt figure was not reported separately from borrowings, notes and derivative instruments.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.